-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

Benzinga·07/07/2026 15:37:24
Listen to the news
RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $29 to $36.